WO1994009760A1 - Biodegradable polymers for cell transplantation - Google Patents

Biodegradable polymers for cell transplantation Download PDF

Info

Publication number
WO1994009760A1
WO1994009760A1 PCT/US1993/010655 US9310655W WO9409760A1 WO 1994009760 A1 WO1994009760 A1 WO 1994009760A1 US 9310655 W US9310655 W US 9310655W WO 9409760 A1 WO9409760 A1 WO 9409760A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
acid
cells
amino
protected
Prior art date
Application number
PCT/US1993/010655
Other languages
French (fr)
Inventor
Denise Barrera
Robert S. Langer
Peter T. Lansbury, Jr.
Joseph P. Vacanti
Original Assignee
Massachusetts Institute Of Technology
Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology, Children's Hospital filed Critical Massachusetts Institute Of Technology
Priority to EP94901280A priority Critical patent/EP0619732B1/en
Priority to DE69329903T priority patent/DE69329903T2/en
Priority to JP51143894A priority patent/JP3288380B2/en
Priority to AT94901280T priority patent/ATE198980T1/en
Priority to CA002127463A priority patent/CA2127463C/en
Publication of WO1994009760A1 publication Critical patent/WO1994009760A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6852Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068General culture methods using substrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25Peptides having up to 20 amino acids in a defined sequence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/30Synthetic polymers
    • C12N2533/40Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer

Definitions

  • the present invention describes the synthesis and applications of a hydrolytically degradable polymer useful in biomedical applications involving the interaction of cells with the polymer structure.
  • transplantation of the liver is often times successful but has plateaued at about 2200 transplants per year because of donor scarcity. Unfortunately, 30,000
  • Microencapsulated Hepatocytes An in vitro and in vivo Study," Biomat.. Art. Cells. Art. Org., 15,
  • transplantation depends on efficiently using the available donor material and providing an environment conducive to long-term cell survival, differentiation and growth.
  • One promising approach is to attach isolated cells and cell clusters onto synthetic biodegradable polymer scaffolds in vitro and then to implant the polymer-cell scaffold into recipients thereby replacing whole organ function with this device (Vacanti, J. P. "Beyond Transplantation, Third Annual Samuel Jason Mixter Lecture,” Archives of
  • This scaffold has several functions. First it must provide for active polymer/cell interactions for most mammalian cells must adhere to a surface in order to survive. It is also essential that this adhesion occur in such a manner that the cells continue to function normally. If the cells survive, but do not function normally, transplanting them into a patient is futile. Next, the polymer scaffold must have suitable surface chemistry to guide and reorganize the cell mass. Finally, the three dimensional structure must be designed to deliver a significant number of cells while allowing for the proper diffusion of nutrients.
  • Biocompatibility is essential in order to prevent acute adverse tissue responses that could impair the function of the transplanted cells.
  • Biodegradability is desired to provide a completely natural tissue replacement without the possibility of chronic tissue reaction to the foreign body.
  • the mechanical properties must allow for easy and
  • Another possible matrix material that is produced commercially is surgical suture material. This is made from polyglycolic acid, polylactic acid and copolymers of glycolic and lactic acid.
  • polymers are well characterized, and the physical strength and fiber forming properties are good
  • a polymer is needed that has the beneficial qualities of polylactic acid but also provides for an easily manipulated surface chemistry.
  • Polymers have been designed which degrade in vivo to non-toxic residues that have biologically active moieties such as amino acids bound to the polymer, either directly or via short side chains.
  • biologically active moieties such as amino acids bound to the polymer, either directly or via short side chains.
  • moieties are coupled to the polymers via free
  • monomers containing amino acids with reactive side chains such as lysine
  • monomers containing amino acids with reactive side chains have been synthesized which are copolymerized with the lactic acid containing monomer, lactide, the glycolic acid containing monomer, glycolide, or any other monomers with similar mechanisms of polymerization.
  • the reactive sites on the amino acids are protected with standard protecting groups.
  • Copolymerized with the lactide, the resulting copolymers are of the form poly (lactic acid-co-amino acid) with the amino acid being incorporated into the backbone via an amide bond. If the percentage of the amino acid subunit is low, in the range of 1-10%, the mechanical properties will not be disrupted.
  • the reactive side chains of the amino acids are made available by removing the protecting group using standard deprotection methods. These reactive side chains are now available for modification by any of the normal methods used in coupling chemistry. In the most preferred embodiment, attachment peptides are bound to the amino acids where they serve to enhance binding of cells to the polymer.
  • Figure 1 is a schematic of the reaction of an ⁇ - hydroxy acid with a protected ⁇ -amino acid to yield the cyclilized hydroxyl acid-co-amino acid.
  • Figures 2A-D is a schematic of the formation of 3-(butyl-4-benzyloxycarbonyl amino)-6-benzyl-2,5-morpholinedione, where an ester bond is formed first and then the product cyclized through amide bond formation, as shown in the prior art.
  • Figure 3 is a schematic of the cyclizing of the ⁇ -hydroxy acid with an ⁇ -amino acid to make alkyl substituted 2,5-morpholinediones, where an a-bromo acyl bromide is utilized as the ⁇ -hydroxy acid
  • Figure 4 is a schematic of a ring opening
  • Figure 5 is a schematic of a desired monomer structure, 3-(Butyl-4-benzyloxycarbonyl amino)-6-methyl-2,5-morpholinedione, a lysine containing monomer.
  • the polymers are characterized by biocompatibility, degradability into non-toxic products normally present in the body, preferably by hydrolysis, and the presence of accessible
  • the polymers are formed by polymerization of ⁇ amino acids with ⁇ hydroxy acids.
  • the biologically active moieties are then coupled to the amino acids via free carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
  • the ⁇ amino acids are generally of the formula: R, R'-COH-CO-OH, wherein R and R' are
  • Examples of ⁇ hydroxy acids include lactic acid and glycolic acid.
  • the ⁇ amino acids are preferably of the formula: R", R'"-CNH 2 -CO-OH, wherein R" and R'" are independently H or a linear or branched alkyl; any protected primary or secondary amino group; any protected ester; any protected hydroxyl; any protected sulfide; any protected amide; any protected guanidino; or any protected imidazole. All 20 of the common amino acids can be used. The most preferred amino acids are protected lysine and protected aspartic acid.
  • Table I shows a broad sample of activated carboxylic acids (Bodanszky, 1988). Each of these has its own advantages, such as side reactions, and disadvantages, such as mild reaction conditions or water solubility.
  • the first method describing the formation of 3-(butyl-4-benzyloxycarbonyl
  • acyl hydrazide which is a "masked" form of the activated acyl azide.
  • ester bond is formed between the 2-hydroxy-3-phenylpropanoic acid hydroxyl group and the lysine carboxylic acid using N-hydroxy succinimide ester activation.
  • the lysine ⁇ -amine group is then deprotected.
  • the lactic acid hydrazide is converted to the acyl azide.
  • the cyclization is completed through amide bond formation.
  • the amide bond is formed by the general method discussed above.
  • the cyclization through the ester bond formation takes place by an SN 2 displacement of the bromine with the sodium salt of the carboxylic acid. This reaction exchanges the roles of the two centers.
  • the carboxylic acid group acts as the nucleophile, while the a-bromo group provides the electrophilic center.
  • the monomers are polymerized using a technique such as melt condensation, as exemplified using polyglycolic acid and polylactic acid.
  • Catalyst that have been used include: tributlytin methoxide, dibutyltin dimethoxide, dibutyltin
  • a-amino acids into the backbone is dimerize them with an a-hydroxy acid, such as lactic acid. This step creates a substituted morpholinedione which can be used in subsequent copolymerizations. Only amino acids with alkyl substituents have been copolymerized in this manner.
  • the substituted morpholinedione contains both an amide bond and an ester bond in the ring. Both of these functional groups could polymerize by a ring opening mechanism using several different types of initiators such as cationic, active hydrogen, anionic, and coordination (Ivin, J. K. and Saegusa, T., eds.. Ring Opening Polymerization, Volumes 1-3, Elseveir Applied Science Publishers, New York, 1984). However, 6-member ring lactams do not polymerize under cationic or active hydrogen initiator conditions (Ivin, 1984). If these conditions are used, the morpholinedione should polymerize through the ester bond.
  • initiators such as cationic, active hydrogen, anionic, and coordination (Ivin, J. K. and Saegusa, T., eds.. Ring Opening Polymerization, Volumes 1-3, Elseveir Applied Science Publishers, New York, 1984).
  • 6-member ring lactams do not polymer
  • the benzoxycarbonyl amino protecting group is common in peptide synthesis, and can be cleaved by the selective method of solid phase catalytic reduction. This reaction is quite mild and should not harm the ester bonds in the backbone of the polymer. However, many other protecting groups and deprotecting
  • the polymer can be cast into a variety of shapes by standard processing techniques, such as solvent casting and compression molding. Solvent casting is used to obtain thin films. Variables that should be considered in order to optimize this processing technique are choice of solvent, concentration of starting solution, solvent evaporation rate, casting surface, and molecular weight of the polymer.
  • Compression molding is used to form small discs by compressing finely ground polymer powder.
  • Variables that are important for compression molding include polymer contact surface, pressure, temperature, cooling rate if appropriate, polymer powder size, and molecular weight of the polymer.
  • the polymer contact surface can greatly influence the composition of the surface of the polymer film or disc.
  • the polymer interfaces with air, whereas, during compression molding, the interface will probably be either metal/polymer or teflon/polymer if a teflon release tape is used.
  • metal/polymer or teflon/polymer if a teflon release tape is used.
  • very hydrophobic interfaces may cause the hydrophilic amino groups to become inaccessible.
  • the choice of solvent in solvent casting may also affect the accessibility of the amino groups.
  • More sophisticated processing techniques such as injection molding, fiber extrusion, fiber weaving, may be essential to obtain optimal cell function
  • Adhesion of cells to the surface of the polymer is enhanced by coupling of biologically active
  • moieties such as GRGDY and YIGSR (standard one letter abbreviations for amino acids are used herein, as listed in 37 C.F.R.), to the reactive side chains of the polymer such as amino groups or carboxylic acids.
  • the reactive side chains may not be accessible to the surface of the polymer device.
  • several methods can be used to increase the surface reactive group accessibility. First, the surface can be exposed to an aqueous solution
  • miscible hydrophilic or polar solvents such as ethanol or acetone.
  • Another way to increase the flexibility of the polymer backbone at the surface is to expose the polymer device to solvent vapors after processing.
  • the first method involves activating the
  • C-terminus carboxylic acid of the peptide and then reacting this group with the amino groups on the polymer surface.
  • the C-terminus carboxylic acid can be activated by several methods as indicated in Table I.
  • a preferred reagent is
  • EDC 1-ethyl-3-(3-dimethylaminopropyl-carbodiimide
  • This activated species will react readily with free amino groups (Yamada, H.; Imoto, T.; Fujita, K.; Okazaki, K.; and Motomura, M.; "Selective Modification of Aspartic Acid-101 in Lysozyme by Carbodiimide Reaction,"
  • carboxylic acid groups one at the C-terminus and the other on the aspartic acid residue. If the C-terminus carboxylic acid is to be used to chemically attach the peptide to the polymer surface then the aspartic acid residue must be protected. A completely protected RGDS peptide can be synthesized by those skilled in the art. After attachment the peptide side chains of the peptide would have to be deprotected.
  • N-hydroxysuccinimide ester at both ends (D'Souza, S. E.; Ginsberg, M. H.; Lam, S. C.-T.; and Plow, E. F., "Chemical Cross-Linking of Arginyl-Glycyl-Aspartic Acid Peptides to an Adhesion Receptor on Platelets," The Journal of Biological Chemistry, 263, 3943-3951 (1988); Staros, J. V., "N-Hydroxysulfosuccinimide Active Esters: Bis(N-hydroxysulfosuccinimide) Esters of Two Dicarboxylic Acids are Hydrophilic,
  • the first step in this approach is to react the polymer surface amino groups with one end of the bifunctional molecule.
  • the peptide is attached to the other end of the molecule through the N-terminus amine. It is not necessary to synthesize a protected peptide as previously mentioned, for there is only one amino group in the peptide in this example.
  • This approach also utilizes a bifunctional molecule which is reactive towards amines at both ends such as carbonyl diimidazole. This bifunctional molecule, the polymer, and the peptide can be dissolved together in a common solvent. Some side reactions may occur, include linking of
  • Cells such as hepatocytes, pancreatic cells, intestinal cells, uroendothelial cells, skin cells, muscle cells, nerve cells, and bone cells which are dissociated and viable and in a suspension are applied to a matrix formed of the polymer. Cells are provided with sufficient time to attach to the polymer, then the matrix is implanted using standard surgical techniques.
  • reaction product is purified by silica gel column chromatography.
  • the eluent is 93/5/2
  • each of the monomers must be recrystallized from ethyl acetate in the N 2 box. These crystals are then dried under vacuum overnight. The monomers are then weighed out into the polymerization flask, 10.9 g lactide (75.3 mM) and 2.77 g protected lysine monomer (8.27 mM).
  • the catalyst solution 1.06 g of stannous octoate in 10 ml of chloroform, 0.262 ⁇ mol/ ⁇ l, is prepared and 305 ⁇ l of the catalyst solution added into the polymerization flask. The chloroform is removed under vacuum. The flask is flushed several times with argon.
  • the protected lysine content was analyzed by standard amino acid analysis and H 1 NMR. Both of these techniques indicate a lysine content of 2% where the maximum is 5%. DSC analysis yields
  • N-e-benzyloxycarbonyl protecting group from the side chain of lysine N-e-benzyloxycarbonyl protecting group from the side chain of lysine.
  • Example 3 acid-co-lysine from Example 3 is ground to a fine powder.
  • the powder 150 mg is put into a die (1.4 cm diameter) and compressed at 10,000 psi for 30 minutes while the top and bottom compression plates are at 100 °C. This type of film can be easily handled, but higher temperatures are necessary to obtain a
  • Example 5 The hydrolytic degradation of the poly
  • Example 4 acid-co-lysine from Example 4 were immersed in PBS pH 7.2 at 37 °C with rotational agitation at 120 rpm.
  • the buffer was changed weekly and the films were sacrificed at various time points. These films degrade more quickly than homopolymers of lactic acid. By five weeks, the Mw of the copolymer was half of its original value and the films had lost integrity, breaking up into many pieces. The remaining weight of the films decreased gradually. By 23 weeks more than 40% of the weight was lost. Lactic acid was also released into the buffer, as determined by an
  • Example 7 GRGDY-peptide attachment to processed films from Example 4.
  • GRGDY peptide 0.5 mg/ml in PBS, pH 7.2
  • Example 8 Cell adhesion to modified films from
  • This example illustrates the ability of cells to adhere the peptide modified films from Example 7.
  • the films from example 7 were sterilized by exposure to ultraviolet radiation for 15 minutes on each side and then placed in a sterile cell adhesion apparatus.
  • the wells were filled with 0.4 ml of serum-free Dulbecco's Modified Eagle Medium and 3T3 mouse fibroblasts were added to the medium so that the initial density was approximately 10,000 cells/cm 2 .
  • the cells were incubated at 37°C for 4 hours, then washed 3 times with Hanks Balanced Salt Solution, and the remaining cells were visually counted.

Abstract

Polymers more suitable for use in organ transplantation are formed by coupling biologically active moieties to the free amino groups of polymers formed by incorporation of α amino acids into polymers formed of alpha hydroxy acids such as lactic acids. In the preferred embodiment, the peptides are coupled to the free amino groups.

Description

BIODEGRADABLE POLYMERS FOR CELL TRANSPLANTATION
Field of the Invention
The present invention describes the synthesis and applications of a hydrolytically degradable polymer useful in biomedical applications involving the interaction of cells with the polymer structure.
Background of the Invention
Over the years, there have been many successful uses of polymers in medicine. Most of these
applications require minimal polymer cell
interactions. Consequently, there has been a lot of work done on minimizing the interactions of these polymer systems with the cells that they come in contact with.
However, one challenge in the area of biomedical materials that has received less attention is the development of substrates that can interact favorably with mammalian cells either in vitro or in vivo . Such materials could be useful for many applications from the basic study of how cells interact with surfaces to applied areas such as in vitro mammalian cell culture for the production of useful materials and in vivo cell transplantation for replacement of lost cellular function.
To illustrate the need for in vivo cell
transplantation, it is worth considering that the success of whole organ transplantation is limited by donor organ availability. As an example,
transplantation of the liver is often times successful but has plateaued at about 2200 transplants per year because of donor scarcity. Unfortunately, 30,000
Americans die every year of liver disease while an additional 5 million Americans are affected. The cost to the economy is more than $14 billion dollars
annually. The situation is similar with other organ systems such as the kidney, pancreas, lung, and heart.
The demand for replacement organs is therefore very high. However, since the function of most of these organs is so complex and in most cases not yet completely understood, synthetically recreating their function is practically impossible. Alternative treatments concentrate on manipulating the smallest functional unit of the organ, the individual cell.
Many groups have attempted cell transplantation under a variety of conditions (Bumgardner, G. L.; Fasola, C.; and Sutherland D. E. R., "Prospects for Hepatocyte Transplantation," Hepatology. 8, 1158-1161 (1988);
Wong, H. and Chang, T. M. S., "The Viability and
Regeneration of Artificial Cell Microencapsulated Rat Hepatocyte Xenograft Transplants in Mice," Biomat., Art. Cells. Art. Org., 16, 731-739 (1988); Vacanti, J. P.; Morse, M. A.; Saltzman, M., Domb, A. J.;
Perez-Atayde, A.; and Langer, R., "Selective Cell Transplantation Using Bioabsorbable Artificial
Polymers as Matrices," Journal of Pediatric Surgery, 23, 3-9 (1988); U. S. Patent, 4,696,286 to Cochrum (1987); Dawson, R. M.; Broughton, R. L.; Stevenson, W. T. K.; and Sefton, M. V., "Microencapsulation of CHO Cells in a Hydroxyethyl Methacrylate-Methyl
Methacrylate Copolymer," Biomaterials, 8, 360-366 (1987); Jaffe, V.; Darby, H.; and Selden, C., "The Growth of Transplanted Liver Cells within the
Pancreas," Transplantation. 45, 497-498 (1987);
Ricordi, C.; Flye, M. W.; and Lacy, P. E., "Renal
Subcapsular Transplantation of Clusters of Hepatocytes in Conjunction with Pancreatic Islets,"
Transplantation. 45, 1148-1151 (1987); Sun, A. M.; Cai, Z.; Shi, Z.; Ma, F.; and O'Shea, G. M.,
"Microencapsulated Hepatocytes: An in vitro and in vivo Study," Biomat.. Art. Cells. Art. Org., 15,
483-496 (1987); Sun, A. M.; O'Shea, G. M.; and Goosen, M. F. A., "Injectable Microencapsulated Islet Cells as a Bioartificial Pancreas," Applied Biochemistry and Biotechnology. 10, 87-99 (1984); Lim, F.,
"Microencapsulation of Living Cells and Tissues,"
Applied Biochemistry and Biotechnology, 10, 81-85 (1984)). When suspensions of cells have been
injected, only small numbers survived. In addition, the cells that did survive had inadequate three dimensional structure and no way to from an
appropriate structure. Some researchers have
encapsulated cells, and this procedure provides excellent protection from the host's immune system. Often times, however, the barrier is too large and does not allow for sufficient exchange between the vascular supply and the cells. Moreover, the body sometimes forms a fibrous capsule around the implant which creates an additional barrier to the flow of nutrients. These approaches have had varying levels of success, but none has yet produced a viable clinical solution to the need for organs for
transplantation.
Clinical success in the area of cell
transplantation depends on efficiently using the available donor material and providing an environment conducive to long-term cell survival, differentiation and growth. One promising approach is to attach isolated cells and cell clusters onto synthetic biodegradable polymer scaffolds in vitro and then to implant the polymer-cell scaffold into recipients thereby replacing whole organ function with this device (Vacanti, J. P. "Beyond Transplantation, Third Annual Samuel Jason Mixter Lecture," Archives of
Surgery. 123, 545-549 (1988)). With this approach, several implants could be obtained from each donor organ or cell material obtained from living donors. This could also help eliminate the need for
immunosuppressive therapy, which is often required following organ transplantation. The key to the success of this cell transplantation technique is in the design of the synthetic polymer scaffold (Cima, L., Ingber, D., Vacanti, J., and Langer, R. Hepatocyte Culture on Biodegradable Polymeric Substrates, Biotech. Bioeng., 38, 145-158, 1991; Cima, L., Vacanti, J., Vacanti, C., Ingber, D., Mooney, D., and Langer, R., Polymer
Matrices for Cell Transplantation and Organ
Regeneration, J. Biomech. Eng., 113, 143-151, 1991). This scaffold has several functions. First it must provide for active polymer/cell interactions for most mammalian cells must adhere to a surface in order to survive. It is also essential that this adhesion occur in such a manner that the cells continue to function normally. If the cells survive, but do not function normally, transplanting them into a patient is futile. Next, the polymer scaffold must have suitable surface chemistry to guide and reorganize the cell mass. Finally, the three dimensional structure must be designed to deliver a significant number of cells while allowing for the proper diffusion of nutrients.
Several criteria can be used to define the ideal substrate. Biocompatibility is essential in order to prevent acute adverse tissue responses that could impair the function of the transplanted cells.
Biodegradability is desired to provide a completely natural tissue replacement without the possibility of chronic tissue reaction to the foreign body. The mechanical properties must allow for easy and
reproducible processing into a variety of shapes, and the resulting devices must maintain their shape once implanted. Finally, the surface chemistry must be easily manipulated so that it can be optimized to meet the needs of each application.
One possible family of matrices that is
commercially available consists of the purified extracellular matrix components, such as fibronectin, laminin, and collagen. Although these matrices provide great biocompatibility and cell adhesion, they do not have sufficient mechanical properties to build a stable three dimensional structure independent of the cells. It is also difficult to obtain high quality matrix material on a consistent basis since it must be harvested from natural sources.
Another possible matrix material that is produced commercially is surgical suture material. This is made from polyglycolic acid, polylactic acid and copolymers of glycolic and lactic acid. The
biocompatibility and biodegradability of these
polymers are well characterized, and the physical strength and fiber forming properties are good
(Gilding, D. K. and Reed, A. M., "Biodegradable
Polymers for Use in Surgery - Polyglycolic /
Poly(lactic acid) Homo- and Copolymers: l. Polymer, 20, 1459-1464 (1979);
U. S. Patent No. 4,048,256 to Casey, D. J. and
Epstein, M., "Normally-Solid, Bioabsorbable,
Hydrolyzable, Polymeric Reaction Product," (1977); Craig, P. H., Williams, J. A.; Davis, K. W., Magoun, A. D., Levy, A. J.; Bogdansky, S.; and Jones, J. P. Jr., "A biologic Comparison of Polyglactin 910 and Polyglycolic Acid Synthetic Absorbable Sutures,"
Surgery. 141, 1-10 (1975); Frazza, E. J. and Schmitt, E. E., "A New Absorbable Suture," J. Biomed. Mater. Res. Symposium. 1, 43-58 (1971)). Also, since these polymers are used as suture material, they have already been approved for implantation.
Unfortunately, the surface of these materials cannot be easily manipulated to provide optimal surface chemistry that could meet the needs of cells for each application.
A polymer is needed that has the beneficial qualities of polylactic acid but also provides for an easily manipulated surface chemistry.
It is therefore an object of the present
invention to provide a biodegradable, biocompatible polymer modified to increase cell adhesion.
It is a further object of the present invention to provide such a polymer that has the physical and mechanical properties that allow the polymer to be processed into a matrix suitable for seeding with cells and implantation into a patient using standard surgical techniques.
Summary of the Invention
Polymers have been designed which degrade in vivo to non-toxic residues that have biologically active moieties such as amino acids bound to the polymer, either directly or via short side chains. In the preferred embodiments, the biologically active
moieties are coupled to the polymers via free
carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids. The resulting polymers have good mechanical and biological
properties.
In the preferred embodiment, monomers containing amino acids with reactive side chains, such as lysine, have been synthesized which are copolymerized with the lactic acid containing monomer, lactide, the glycolic acid containing monomer, glycolide, or any other monomers with similar mechanisms of polymerization. The reactive sites on the amino acids are protected with standard protecting groups. Copolymerized with the lactide, the resulting copolymers are of the form poly (lactic acid-co-amino acid) with the amino acid being incorporated into the backbone via an amide bond. If the percentage of the amino acid subunit is low, in the range of 1-10%, the mechanical properties will not be disrupted. However, higher percentages may be desirable for certain applications, even though the mechanical properties may not be quite as good. The reactive side chains of the amino acids are made available by removing the protecting group using standard deprotection methods. These reactive side chains are now available for modification by any of the normal methods used in coupling chemistry. In the most preferred embodiment, attachment peptides are bound to the amino acids where they serve to enhance binding of cells to the polymer.
Brief Description of the Drawings
Figure 1 is a schematic of the reaction of an α- hydroxy acid with a protected α-amino acid to yield the cyclilized hydroxyl acid-co-amino acid.
Figures 2A-D is a schematic of the formation of 3-(butyl-4-benzyloxycarbonyl amino)-6-benzyl-2,5-morpholinedione, where an ester bond is formed first and then the product cyclized through amide bond formation, as shown in the prior art.
Figure 3 is a schematic of the cyclizing of the α-hydroxy acid with an α-amino acid to make alkyl substituted 2,5-morpholinediones, where an a-bromo acyl bromide is utilized as the α-hydroxy acid
equivalent, as shown in the prior art.
Figure 4 is a schematic of a ring opening
polymerization for lactic acid, as shown in the prior art.
Figure 5 is a schematic of a desired monomer structure, 3-(Butyl-4-benzyloxycarbonyl amino)-6-methyl-2,5-morpholinedione, a lysine containing monomer.
Detailed Description of the Invention
Methods for synthesis of polymers having
advantageous properties for implantation and cell culture are described. The polymers are characterized by biocompatibility, degradability into non-toxic products normally present in the body, preferably by hydrolysis, and the presence of accessible
biologically active moieties bound to the polymers by amino acids polymerized within the polymer or
chemically coupled to the polymer.
In the preferred embodiments, the polymers are formed by polymerization of α amino acids with α hydroxy acids. The biologically active moieties are then coupled to the amino acids via free carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
Synthesis of the Amino Acid containing Monomer The general concept for producing the monomer in Figure 1, referred to herein as the amino acid monomer, is to cyclize an α-hydroxy acid with an α-amino acid to yield a
3,6-disubstituted-2,5-morpholinedione.
The α amino acids are generally of the formula: R, R'-COH-CO-OH, wherein R and R' are
independently H or a linear or branched alkyl.
Examples of α hydroxy acids include lactic acid and glycolic acid.
The α amino acids are preferably of the formula: R", R'"-CNH2-CO-OH, wherein R" and R'" are independently H or a linear or branched alkyl; any protected primary or secondary amino group; any protected ester; any protected hydroxyl; any protected sulfide; any protected amide; any protected guanidino; or any protected imidazole. All 20 of the common amino acids can be used. The most preferred amino acids are protected lysine and protected aspartic acid.
This transformation involves producing an amide bond and an ester bond. All synthetic routes are variations of two main themes: 1) formation of the ester bond and then cyclization via amide bond
formation or 2) formation of the amide bond and then cyclization via ester bond formation.
Several standard reactions are used to form amide bonds. In general, these reactions consist of
activating the carboxylic acids to facilitate
nucleophilic attack. Table I shows a broad sample of activated carboxylic acids (Bodanszky, 1988). Each of these has its own advantages, such as side reactions, and disadvantages, such as mild reaction conditions or water solubility.
Figure imgf000012_0001
Ester bond formation is more difficult in general and requires more sophisticated methods. Not only is the carboxylic acid activated but catalysts such as 4-dimethylaminopyridine are also used. It is
important to note that during the formation of the first bond, either the ester or amide, the other reactive species must be protected. Table II
(Bodanszky, 1988) provides a list of the more common protecting groups, which can also be referred to as blocking groups, along with the deprotecting
conditions.
Figure imgf000014_0001
Two methods are applicable to the synthesis of the amino acid monomer. The first method, describing the formation of 3-(butyl-4-benzyloxycarbonyl
amino) -6-benzyl-2,5-morpholinedione, is by Yasutake, A.; Miyazaki, K., Aoyagi, H., Kato, T., and Izumiya, N., "Cyclic Peptides: VIII. Synthesis and Tryptic Hydrolysis of Cyclic Depsidipeptides Containing a Lysine Residue," Int. J. Peptide Protein Res., 16, 61-65 (1980). An ester bond is formed first and then the product cyclized through amide bond formation. The synthetic pathway used is shown in Figure 2. In this synthesis, one carboxyl is protected as an acyl hydrazide which is a "masked" form of the activated acyl azide. First, the ester bond is formed between the 2-hydroxy-3-phenylpropanoic acid hydroxyl group and the lysine carboxylic acid using N-hydroxy succinimide ester activation. The lysine α-amine group is then deprotected. Next, the lactic acid hydrazide is converted to the acyl azide. Finally, the cyclization is completed through amide bond formation.
A second approach to cyclizing the α-hydroxy acid with the α-amino acid is shown in Figure 3. This pathway is used to make alkyl substituted
2 , 5-morpholinediones (Samyn, C. and Van Beylen, M., "Polydepsipeptides: Ring-Opening Polymerization of 3-Methyl-2,5-Morpholinedione,
3,6-Dimethyl-2,5-Morpholinedione and Copolymerization thereof with D,L-Lactide, " Makromol. Chem., Macromol. Symp. , 19, 225-234 (1988); Helder, J., Kohn, F. E., Sato, S.; van den Berg, J. W., and Feijen, J.,
"Synthesis of Poly
[Oxyehylidenecarbonylimino-(2-Oxoethylene)]
[Poly(Glycine-D,L-Lactic Acid)] by Ring Opening
Polymerization," Makromol. Chem., Rapid Commun., 6, 9-14 (1985); Greenstein, J. P. and Winitz, M.,
Chemistry of the Amino Acids, Vol . 2 , p 887-901, John Wiley and Sons, Inc., New York, 1961). An a-bromo acyl bromide is utilized as the a-hydroxy acid
equivalent. The amide bond is formed by the general method discussed above. The cyclization through the ester bond formation takes place by an SN2 displacement of the bromine with the sodium salt of the carboxylic acid. This reaction exchanges the roles of the two centers. The carboxylic acid group acts as the nucleophile, while the a-bromo group provides the electrophilic center.
Polymerization
The monomers are polymerized using a technique such as melt condensation, as exemplified using polyglycolic acid and polylactic acid.
Historically, polyglycolic acid was first
produced by condensation polymerization of hydroxy acetic acid (Higgins, 1954 and Beck, 1952). However, there are many problems associated with condensation polymerizations, including long reaction times to obtain even moderate molecular weight products, side reactions which create the necessity for by-product removal, and a lack of end group control (Brode, G. L. and Koleske, J. V., "Lactone Polymerization and
Polymer Properties," J. Macromol. Sci.-Chem., A6, 1109-1144 (1972)), for example, when dimerization to form glycolide competes with chain extension.
In 1954 Lowe (8.Lowe, C. E., "Preparation of High Molecular Weight Polyhydroxyacetic Ester," U. S.
Patent, 2,668,162 (1954).
Mooney, D., Hansen, L., Vacanti, J., Langer, R.,
Farmer, S, and Ingber, D., Switching between growth and differential in hepatocytes: Control by
extracellular matrix, J. Cell Biol.,
submitted)modified the reaction conditions of the polycondensation to obtain high yields of glycolide. This product was then purified and found to polymerize by a ring-opening mechanism to very high molecular weights using antimony trioxides or antimony
trihalides. An example of this ring opening
polymerization is given in Figure 4 for lactic acid. Catalyst that have been used include: tributlytin methoxide, dibutyltin dimethoxide, dibutyltin
diacetate, debutyltin oxide, dibutyltin dichloride, tin dioxide, tin dibromide, tin dichloride, tin tetrabromide, tin tetrachloride, tetraphenyl tin, lead oxide, zinc oxide, zinc, antimony trioxide, triethyl aluminum, aluminum bromide, triisobutyl aluminum, triisopropyl aluminum, magnesium acetate, magnesium stearate, magnesium 2,4-pentanedionate, magnesium ethoxide, magnesium oxide, and stannous octoate, with stannous octoate being the preferred catalyst
(Gilding, D. K., Reed, A. M., and Askill, I. N.,
"Calibration in Gel Permeation Chromatography:
Primary, Universal and Empirical Methods," Polymer. 22, 505-512 (1981).
; U. S. Patent, 3,839,297 to Wasserman, D. and
Versfeit, C. C., "Use of Stannous Octoate Catalyst in the Manufacture of L(-)Lactide-Glycolide Copolymer Sutures," (1974); Frazza, 1971; Higgins, N. A.,
"Condensation Polymers of Hydroxyacetic Acid," U. S. Patent, 2,676,945 (1954); Kohn, F. E.; Ommen, J. G. van; and Feijen, J., "The Mechanism of the
Ring-Opening Polymerization of Lactide and Glycolide," Eur. Polym. J., 19, 1081-1088 (1983); Kohn, F. E.; Van Den Berg, J. W. A., and Van De Ridder, G., "The
Ring-Opening Polymerization of D,L-Lactide in the Melt Initiated with Tetraphenyltin, " Journal of Applied Polymer Science. 29, 4265-4277 (1984); Donald, R. C; Tice, T. R., Gilley, R. M., and English, J. P., "[8] Poly (lactide-co-glycolide) Microcapsules for
Controlled Release of Steroids," Methods in
Enzvmology. 112, 101-116 (1985); Dunsing, R and
Kricheldorf, H. R., "Polylactones: 5. Polymerization of L,L-Lactide by Means of Magnesium Salts," Polymer Bulletin. 14, 491-495 (1985); Sawan, S. P. and Barry, J. J., "Quantitation of Poly (d,1-Lactic Acid)
Degradation Products by HPLC," Polymer Preprints. 29, 299-300 (1988); Kricheldorf, H. R., Jonte, J. M., and Berl, M., "Polylactones: 3. Copolymerization of
Glycolide with L,L-Lactide and other Lactones,"
Makromol. Chem.. Suppl.. 12, 25-38 (1985);
Kricheldorf, H. R. and Sumbel, M., "Polylactones - 18. Polymerization of L,L-Lactide with Sn(II) and Sn(IV) Halogenides," Eur. Polym. J. , 25, 585-591 (1989).
The mechanism of the ring-opening polymerization of glycoside and lactide with stannous octoate is still under debate, but a nonionic insertion mechanism has gained the most acceptance (Kohn, 1984; Leenslag, J. W. and Pennings, A. J., "Synthesis of High Molecular Weight Poly(L-Lactide) Initiated with Tin
2-Ethylhexanoate, " Makromol. Chem.. 188, 1809-1814 (1987); Kricheldorf, 1989).
Copolymerization with 2,5-Morpholinedione.
Recently, there has been an attempt to
incorporate amino acid units into the backbone of polylactic acid in order to expand the range of properties available from this bioabsorbable material (Veld, P. J. A. in 't; Dijkstra, P. J., Lochem, J. H. van; and Feijen, J., "Synthesis of Alternating
Polydepsipeptides by Ring-Opening Polymerization of Morpholine-2, 5-Dione Derivatives, " Makromol. Chem., 191, 1813-1825 (1990); Samyn 1988; Helder, J. and Feijen, J., "Copolymer of D,L-Lactic Acid and
Glycine," Makromol. Chem., Rapid Commun., 7 , 193-198 (1986); Yonezawa, N., Toda, F., and Hasegawa, M., "Synthesis of Polydepsipeptides: Ring-opening
Polymerization of 6-Isopropylmorphiline-2,5-dione and 6-Isopropyl-4-Methylmorpholine-2,5-dione, " Makromol. Chem., Rapid Commun., 6, 607-611 (1985)). The
accepted way to insert the a-amino acids into the backbone is to dimerize them with an a-hydroxy acid, such as lactic acid. This step creates a substituted morpholinedione which can be used in subsequent copolymerizations. Only amino acids with alkyl substituents have been copolymerized in this manner.
The substituted morpholinedione contains both an amide bond and an ester bond in the ring. Both of these functional groups could polymerize by a ring opening mechanism using several different types of initiators such as cationic, active hydrogen, anionic, and coordination (Ivin, J. K. and Saegusa, T., eds.. Ring Opening Polymerization, Volumes 1-3, Elseveir Applied Science Publishers, New York, 1984). However, 6-member ring lactams do not polymerize under cationic or active hydrogen initiator conditions (Ivin, 1984). If these conditions are used, the morpholinedione should polymerize through the ester bond.
It is expected that this ester bond will have a reactivity very similar to the reactivity of the ester bonds in lactide, due to the fact that the amide structure with its partial double bond character will increase the ring strain. Copolymerizations with lactide and methyl substituted morpholinediones at monomer ratios of 1:1 yielded polymers with a mole ratio of monomer units of 1:1 within experimental error (Samyn 1988; Helder, 1986; Yonezawa, 1985).
This result suggests that the two ester bonds have similar reactivities.
Deprotection of amino groups
The removal of the amino protecting groups is essential. If this step is not completed, there will be no reactive groups available for the attachment of the biologically active moieties.
The benzoxycarbonyl amino protecting group is common in peptide synthesis, and can be cleaved by the selective method of solid phase catalytic reduction. This reaction is quite mild and should not harm the ester bonds in the backbone of the polymer. However, many other protecting groups and deprotecting
conditions are available, as indicated in Table I (Greene, T. W., Protective Groups in Organic
Synthesis, 239-241,John Wiley and Sons, Inc., New York, (1981)).
An alternative route to the deprotection is to deprotect only the surface of a polymer device that had been processed before any deprotection reactions. This method of deprotection could be completed with mildly alkaline reagents that would hydrolyze the bonds at the surface. Of course, both the ester bonds in the backbone of the polymer as well as the bonds of the protecting groups would be hydrolyzed. This surface degradation should not affect the desired mechanical properties. However, the protecting groups in the bulk of the sample would be unaffected.
Polymer Processing
The polymer can be cast into a variety of shapes by standard processing techniques, such as solvent casting and compression molding. Solvent casting is used to obtain thin films. Variables that should be considered in order to optimize this processing technique are choice of solvent, concentration of starting solution, solvent evaporation rate, casting surface, and molecular weight of the polymer.
Compression molding is used to form small discs by compressing finely ground polymer powder. Variables that are important for compression molding include polymer contact surface, pressure, temperature, cooling rate if appropriate, polymer powder size, and molecular weight of the polymer.
The polymer contact surface can greatly influence the composition of the surface of the polymer film or disc. During solvent casting the polymer interfaces with air, whereas, during compression molding, the interface will probably be either metal/polymer or teflon/polymer if a teflon release tape is used. There is a concern that very hydrophobic interfaces may cause the hydrophilic amino groups to become inaccessible. The choice of solvent in solvent casting may also affect the accessibility of the amino groups.
More sophisticated processing techniques such as injection molding, fiber extrusion, fiber weaving, may be essential to obtain optimal cell function,
especially in the case of hepatocytes. These methods are known to those skilled in the art.
Adhesion Moiety Attachment
Adhesion of cells to the surface of the polymer is enhanced by coupling of biologically active
moieties, such as GRGDY and YIGSR (standard one letter abbreviations for amino acids are used herein, as listed in 37 C.F.R.), to the reactive side chains of the polymer such as amino groups or carboxylic acids.
Surface Activation
In the event that the reactive side chains may not be accessible to the surface of the polymer device, several methods can be used to increase the surface reactive group accessibility. First, the surface can be exposed to an aqueous solution
containing miscible hydrophilic or polar solvents such as ethanol or acetone. Such exposure should increase the flexibility of the polymer backbone by lowering Tg. This increased flexibility will allow the reactive groups to move to the surface while the hydrophilic nature of the aqueous solution will provide the driving force.
Another way to increase the flexibility of the polymer backbone at the surface is to expose the polymer device to solvent vapors after processing.
Polar solvents should provide a greater driving force for the reactive groups to move to the surface. Attachment Chemistry
It is important for optimal cellular function to be able to manipulate the surface chemistry of the polymer device. An important example of this is the attachment of an RGD peptide which has been shown to promote cell adhesion. The attachment of this adhesion moiety to the reactive side chains such as free amino groups on the polymer surface can be achieved by either of two methods.
The first method involves activating the
C-terminus carboxylic acid of the peptide, and then reacting this group with the amino groups on the polymer surface. The C-terminus carboxylic acid can be activated by several methods as indicated in Table I. A preferred reagent is
1-ethyl-3-(3-dimethylaminopropyl-carbodiimide (EDC) which produces an O-acyl-isourea. This activated species will react readily with free amino groups (Yamada, H.; Imoto, T.; Fujita, K.; Okazaki, K.; and Motomura, M.; "Selective Modification of Aspartic Acid-101 in Lysozyme by Carbodiimide Reaction,"
Biochemistry, 20, 4836-4842 (1981); Hoare, D. G. and Koshland, D. E. Jr., "A Method for the Quantitative Modification and Estimation of Carboxylic Acid Groups in Proteins," The Journal of Biological Chemistry, 242, 2447-2453 (1967); Sheehan, J. C.; Preston, J.; Cruickshank, P. A., "A Rapid Synthesis of Oligopeptide Derivatives without Isolation of Intermediates,"
Journal of the American Chemical Society. 87,
2492-2493 (1965)). However, biologically active moieties such as the RGDS peptide contain two
carboxylic acid groups, one at the C-terminus and the other on the aspartic acid residue. If the C-terminus carboxylic acid is to be used to chemically attach the peptide to the polymer surface then the aspartic acid residue must be protected. A completely protected RGDS peptide can be synthesized by those skilled in the art. After attachment the peptide side chains of the peptide would have to be deprotected.
An alternative approach is to link the peptide to the polymer surface through a bifunctional molecule which is reactive towards amines at both ends. An example of such a bifunctional molecule is
bis(sulfosuccinimidyl) suberate which has an
N-hydroxysuccinimide ester at both ends (D'Souza, S. E.; Ginsberg, M. H.; Lam, S. C.-T.; and Plow, E. F., "Chemical Cross-Linking of Arginyl-Glycyl-Aspartic Acid Peptides to an Adhesion Receptor on Platelets," The Journal of Biological Chemistry, 263, 3943-3951 (1988); Staros, J. V., "N-Hydroxysulfosuccinimide Active Esters: Bis(N-hydroxysulfosuccinimide) Esters of Two Dicarboxylic Acids are Hydrophilic,
Membrane-Impermeant, Protein Cross-Linkers,"
Biochemistry. 21, 3950-3955 (1982)). Another commonly used bifunctional linking reagent which reacts with amino groups is glutaraldehyde (Weston, P. D. and Avrameas, S., "Proteins Coupled to Polyacrylamide Beads Using Glutaraldehyde," Biochemical and
Biophysical Research Communications. 45, 1574-1580 (1971); arayanan, S. R.; Kakodkar, S. V.; and Crane, L. J., "'Glutaraldehyde-P', a Stable, Reactive
Aldehyde Matrix for Affinity Chromatography,"
Analytical Biochemistry, 188, 278-284 (1990)). The first step in this approach is to react the polymer surface amino groups with one end of the bifunctional molecule. Next, the peptide is attached to the other end of the molecule through the N-terminus amine. It is not necessary to synthesize a protected peptide as previously mentioned, for there is only one amino group in the peptide in this example.
Bulk Attachment
Since this is a biodegradable polymer, surface modification may be insufficient. The surface layer could degrade away before performing its function. Consequently, bulk attachment strategies have also been considered. This approach also utilizes a bifunctional molecule which is reactive towards amines at both ends such as carbonyl diimidazole. This bifunctional molecule, the polymer, and the peptide can be dissolved together in a common solvent. Some side reactions may occur, include linking of
polymer-polymer and peptide-peptide, but these should not interfere excessively with the linking reaction of the polymer-peptide.
Seeding of Matrix with Cells
Cells such as hepatocytes, pancreatic cells, intestinal cells, uroendothelial cells, skin cells, muscle cells, nerve cells, and bone cells which are dissociated and viable and in a suspension are applied to a matrix formed of the polymer. Cells are provided with sufficient time to attach to the polymer, then the matrix is implanted using standard surgical techniques.
The teachings of the cited publications are indicative of the level of skill and the general knowledge of those skilled in the art. To the extent necessary, the publications are specifically
incorporated herein by reference.
The present invention will be further understood by reference to the following non-limiting examples. Example l: Preparation of
3-(butyl-4-benzyloxycarbonyl
amino)-6-methy1-2,5-morpholinedione. This example illustrates the preparation of
3-(butyl-4-benzyloxycarbonyl
amino)-6-methyl-2,5-morpholinedione, a monomer
containing lactic acid and lysine where the side chain amino group of lysine is protected with a
benzyloxycarbonyl group, as shown in Figure 5. In the final monomer product, both the lactic acid and lysine are in the L configuration. Weighed out:
50.0 g of D-alanine (0.56 M, MW=89.09)
104.3 g of NaNO2 (1.51 M, MW=69.0)
700 g of Na2SO4 (4.93 M, MW=142.0)
Carefully add 580 ml of 48% HBr (5.19 M, MW=80.9) to 2420 ml of ice water. Stir with an overhead mixer. The temperature is -10 °C. Add the D-alanine and let it dissolve. Slowly add the NaNO2to the D-alanine mixture over about 20 minutes. Next, slowly add the Na2SO4 to the mixture over about 20 minutes. Continue to add ice to keep the mixture at -10 °C during the additions. After everything is added, continue to stir until the mixture reaches room temperature, about 1.5 hours. Decant the liquid from the remaining solids. Extract the water with ethyl ether. Dry the ethyl ether with Na2SO4 and then CaCl2. Filter the ethyl ether and then remove the ethyl ether under vacuum. Repeat procedure up to this point. Mix the two batches. Vacuum distill using water aspirator. Collect fraction from 103-106 °C. The product is D-2-bromo propionic acid and the yield is 60% , which is 103.9 g (0.68 M).
Add 70 ml (114.5 g, 0.96 M) of SOCl2 to the 103.9 g of D-2-bromo propionic acid. Heat to 60 °C for 7.5 hours. Collect product by vacuum distillation using a water aspirator. Collect fraction from 45-56 °C. The product is D-2-bromo propionyl chloride and the yield is 74% which is 86.3 g (0.50 M). IR spectroscopy shows the typical acyl chloride peak at 1775 cm"1 and the 1H NMR spectroscopy shows a quartet centered around 4.65 ppm and a doublet at 1.9 ppm.
Dilute 27.6 g (0.16 M) of the D-2-bromo propionyl chloride with 200-400 ml of chloroform. Prepare a slurry of N-e-benzyloxycarbonyl-L-lysine (96.6 g, 0.34 M) in 2000 ml dry chloroform. Add the D-2-bromo propionyl chloride solution to the slurry all at once. Let react at room temperature for 24 hours. The insoluble N-e-benzyloxycarbonyl-L-lysine will react with the D-2-bromo propionyl chloride and form a soluble product and an insoluble impurity. Next, remove the solid impurity by filtration, and then remove all but 600 ml of the chloroform under vacuum. This reaction forms the amide bond between the lysine a-amino group and the lactic acid activated carboxylic acid.
Next, 24.2 ml (18.0 g, 0.14 M) of diisopropyl ethyl amine is diluted in 50 ml of chloroform and then added to the chloroform mixture from the last step. This reaction mixture is then diluted with chloroform to a total of 900 ml. The reaction is heated to reflux and left to react at this temperature for 24 hours. This reaction forms a ring structure through the ester bond between the activated a-hydroxyl of lactic acid and the carboxylic acid of the lysine.
Inversion occurs at the lactic acid center. Upon completion of the reaction, the chloroform is removed under vacuum. A waxy solid forms. This crude
reaction product is purified by silica gel column chromatography. The eluent is 93/5/2
chloroform/methanol/acetic acid. The eluent is removed under vacuum with heating to 60 °C. A viscous oil forms. The product is crystallized by washing the viscous oil with petroleum ether. A yellowish/white powder forms. This powder is recrystallized from ethyl acetate which produces a clean white powder.
The yield is for these last two steps combined is 31% which is 16.6 g, 0.05 M. Melting point 135-136 °C. High resolution mass spectroscopy confirmed elemental analysis; expected 334.15287 amu, experimental
334.1527 amu. The IR and NMR were also consistent. Example 2: Copolymerization of the monomer
produced in Example 1 with lactide to make poly (lactic
acid-co-N-e-benzyloxycarbonyl lysine).
This is an example of the copolymerization of the monomer produced in Example 1 with lactide to make poly (lactic acid-co-N-e-benzyloxycarbonyl lysine).
First the polymerization flask must be
siliconized to rid the glass surface of all hydroxyl groups. Throughout the polymerization procedure, all the glassware is dried in a 130 °C oven overnight and cooled under vacuum. All parts of the experiment requiring that the monomers be exposed to the
atmosphere were done in a N2 box.
The day before the polymerization, each of the monomers must be recrystallized from ethyl acetate in the N2 box. These crystals are then dried under vacuum overnight. The monomers are then weighed out into the polymerization flask, 10.9 g lactide (75.3 mM) and 2.77 g protected lysine monomer (8.27 mM). The catalyst solution, 1.06 g of stannous octoate in 10 ml of chloroform, 0.262 μmol/μl, is prepared and 305 μl of the catalyst solution added into the polymerization flask. The chloroform is removed under vacuum. The flask is flushed several times with argon. The flask was sealed under vacuum and transferred to 100 °C oven for 24 hours, removed from the oven and the reaction quenched in the freezer. Molecular weight before purification: Mn=72,700, Mw=72,200, Mz=88,700. The polymer was purified by dissolving in chloroform and precipitating into methanol. The yield is 80.5% which is 10.96 g. Molecular weight after purification:
Mn=41,800, Mw=79,300, Mz=141,700. Transesterification occurred during the time that the polymer was
dissolved which broadened the molecular weight
distribution. The protected lysine content was analyzed by standard amino acid analysis and H1 NMR. Both of these techniques indicate a lysine content of 2% where the maximum is 5%. DSC analysis yields
Tm=158.0 °C and Tg=55.1 °C.
Example 3: Removal of the N-e-benzyloxycarbonyl protecting group from the side chain of lysine.
This is an example of removing the
N-e-benzyloxycarbonyl protecting group from the side chain of lysine.
All the glassware was dried overnight in a 130 °C oven and cooled under argon. To the reaction vessel was added 225 ml SiEt3H (1.4 M) , 9.9 g of the copolymer from example 2, 225 ml methylene chloride, 1.8 g PdCl2 (0.010 M), and 2.1 ml NEt3 (0.016 M) in the order listed. The reaction was stirred at room temperature for five days. The catalyst, PdCl2, was removed by filtration. 150 ml of methanol was added and let stand 10 minutes, then the solution dumped into excess methanol, approximately 3000 ml. Let stand 30
minutes, and then the precipitate collected by vacuum filtration. The polymer was dried under vacuum. The product from this reaction is poly (lactic
acid-co-lysine). The yield is 79% which is 7.8 g.
The molecular weights are: Mn=31,500, Mw=44,100, Mz=69,700. Proton NMR indicates that 75% of the protecting residues were removed while amino acid analysis indicates that 88% of the lysine units remain in the polymer. The IR spectrum was consistent and DSC analysis shows two melting peaks with the onset of the more intense peak at Tm=159.2 °C and Tg=55.7 °C. Example 4: Processing of the copolymer synthesized in Example 3.
This example illustrates the processibility of the copolymer synthesized in example 3.
Solvent Casting: Poly (lactic acid-co-lysine) from Example 3 (100 mg) was weighed out into a
standard 10 ml glass beaker. Chloroform (2 ml) was added to dissolve the polymer. The chloroform was allowed to evaporate very slowly over a 48 hour period. In order to remove the film from the beaker it was submersed in water for 4 hours. The free standing film is easily handled without breaking and can be cut with a razor blade or scissors. Its appearance is translucent.
Compression Molding: Poly (lactic
acid-co-lysine) from Example 3 is ground to a fine powder. The powder (150 mg) is put into a die (1.4 cm diameter) and compressed at 10,000 psi for 30 minutes while the top and bottom compression plates are at 100 °C. This type of film can be easily handled, but higher temperatures are necessary to obtain a
translucent film. Higher temperatures also cause the film to become brittle.
Example 5: The hydrolytic degradation of the poly
(lactic acid-co-lysine) .
This example illustrates the hydrolytic
degradation of the poly (lactic acid-co-lysine) described in example 3.
The solvent cast films of poly (lactic
acid-co-lysine) from Example 4 were immersed in PBS pH 7.2 at 37 °C with rotational agitation at 120 rpm.
The buffer was changed weekly and the films were sacrificed at various time points. These films degrade more quickly than homopolymers of lactic acid. By five weeks, the Mw of the copolymer was half of its original value and the films had lost integrity, breaking up into many pieces. The remaining weight of the films decreased gradually. By 23 weeks more than 40% of the weight was lost. Lactic acid was also released into the buffer, as determined by an
enzymatic assay. Example 6: Bulk attachment of GRGDY-peptide into polymer synthesized in Example 3
This is an example of the attachment of the GRGDY peptide onto the primary amino groups of the bulk polymer synthesized in Example 3.
The polymer from Example 3 (102 mg) was dissolved in 1 ml of dichloromethane and then 1.5 ml of
dimethylsulfoxide was added. The GRGDY peptide (1.15 mg, 2.0 μmol) was dissolved in 1 ml of
dimethylsulfoxide. A solution of carbonyldiimidazole (CDI) was prepared in dichloromethane at a
concentration of 10 mg/ml, 0.0627 mmol/ml. The polymer and peptide solutions were combined, and then, 0.375 ml (equivalent to 23.1 μmol) of the 10 mg/ml solution of CDI was added over a 4 hour period. The dicholoromethane was removed by evaporation and 5 ml of water was added. The polymer precipitated and was collected by vacuum filtration. Amino acid analysis of the peptide modified sample yielded 3 μmol of peptide/g of polymer. Appropriate controls contained no peptide.
Example 7: GRGDY-peptide attachment to processed films from Example 4.
This is an example of modifying the surface of solvent cast films from Example 4 with the GRGDY adhesion peptide.
Solvent cast films from Example 3 were immersed in 10% aqueous acetone for one hour and then rinsed in 0.01 N pyridine. Next the films were activated with glutaraldehyde (5% in 0.01 N aqueous pyridine buffer, pH= 6.0) for 3 hours, rinsed with 0.01 N pyridine, pH 6.0 for 1-2 minutes and then exposed to the GRGDY peptide (0.5 mg/ml in PBS, pH 7.2) for 16 hours.
After 16 hours, the films were rinsed for 2 minutes each in a series of 6 buffers or water: 0.01 N
pyridine, pH 6.0; deionized water; 0.1 M sodium
acetate, pH 5.5; 1 M sodium chloride; phosphate buffered saline, pH 7.2; and deionized water (in that order).
Example 8: Cell adhesion to modified films from
Example 7.
This example illustrates the ability of cells to adhere the peptide modified films from Example 7.
The films from example 7 were sterilized by exposure to ultraviolet radiation for 15 minutes on each side and then placed in a sterile cell adhesion apparatus. The wells were filled with 0.4 ml of serum-free Dulbecco's Modified Eagle Medium and 3T3 mouse fibroblasts were added to the medium so that the initial density was approximately 10,000 cells/cm2. The cells were incubated at 37°C for 4 hours, then washed 3 times with Hanks Balanced Salt Solution, and the remaining cells were visually counted. The percentage of cells that remained on the peptide modified surface was higher (26 ± 1 %, n=6) than on untreated surfaces (6 ± 8 %, n=6).
Modifications and variations of the present invention will be obvious to those skilled in the art from the foregoing detailed description. Such
modifications and variations are intended to come within the scope of the appended claims.

Claims

We claim:
1. A biodegradable, biocompatible polymer formed by polymerization of monomers formed by α amino acids and α hydroxy acids.
2. The polymer of claim 1 wherein the α amino acids are generally of the formula:
R, R'-COH-CO-OH, wherein R and R' are
independently H or a linear or branched alkyl. R,
3. The polymer of claim 1 wherein the α amino acids are generally of the formula:
R'', R'''-CNH2-CO-OH, wherein R" and R"' are independently H or a linear or branched alkyl; any protected primary or secondary amino group; any protected ester; any protected hydroxyl; any protected sulfide; any protected amide; any protected guanidino; or any protected imidazole.
4. The polymer of claim 1 wherein the α hydroxy acids are selected from the group consisting of lactic acid, glycolic acid, hydroxybutyric acid, and valeric acid.
5. The polymer of claim 1 wherein the amino acid is lysine.
6. The polymer of claim 1 wherein biologically active moieties are coupled to free carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
7. The polymer of claim 6 wherein the
biologically active moieties are selected from the group consisting of GRGDY, YIGSR and other RGD
peptides.
8. A process for making a biocompatible,
biodegradable polymer comprising forming a
prepolymer by chemically coupling an α amino acid and an α hydroxy acid and
polymerizing the monomers.
9. The process of claim 8 wherein the α amino acids are generally of the formula:
R, R'-COH-CO-OH, wherein R and R' are
independently H or a linear or branched alkyl.
10. The process of claim 8 wherein the α amino acids are generally of the formula:
R", R'"-CNH2-CO-OH, wherein R" and R"' are independently H or a linear or branched alkyl; any protected primary or secondary amino group; any protected ester; any protected hydroxyl; any protected sulfide; any protected amide; any protected guanidino; or any protected imidazole.
11. The process of claim 8 wherein the α hydroxy acids are selected from the group consisting of lactic acid, glycolic acid, hydroxybutyric acid, and valeric acid.
12. The process of claim 8 wherein the amino acid is lysine.
13. The process of claim 8 further comprising coupling biologically active moieties to free
carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
14. The process of claim 13 wherein the
biologically active moieties are selected from the group consisting of GRGDY, YIGSR and other RGD
peptides.
15. The process of claim 13 further comprising forming the polymer into a matrix for seeding with cells.
16. The process of claim 15 further comprising seeding the matrix with cells.
17. A method for implanting cells into an animal comprising forming a matrix of a biocompatible, biodegradable polymer having biologically active moieties chemically coupled to the polymer.
18. The method of claim 17 wherein the polymer is prepared from prepolymers formed by chemically coupling an α amino acid and an α hydroxy acid,
polymerizing the monomers, and
coupling biologically active moieties to free carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
19. The process of claim 18 wherein the α hydroxy acids are cyclized with an α-hydroxy acid with an α-amino acid to yield a
3,6-disubstituted-2,5-morpholinedione.
20. The process of claim 17 wherein the α amino acids are generally of the formula:
R, R'-COH-CO-OH, wherein R and R' are
independently H or a linear or branched alkyl.
21. The process of claim 17 wherein the α hydroxy acids are selected from the group consisting of lactic acid, glycolic acid, hydroxybutyric acid, and valeric acid.
22. The process of claim 17 wherein the amino acid is lysine.
23. The process of claim 17 wherein the
biologically active moieties are selected from the group consisting of GRGDY, YIGSR and other RGD
peptides.
24. The process of claim 17 further comprising forming the polymer into a matrix suitable for seeding with cells.
25. The process of claim 24 further comprising seeding the matrix with cells.
26. The process of claim 24 wherein the cells are selected from the group consisting of hepatocytes, pancreatic cells, intestinal cells, uroendothelial cells, skin cells, muscle cells, nerve cells, and bone cells.
27. The process of claim 25 further comprising implanting the matrix seeded with cells.
28. A biocompatible, biodegradable polymer having biologically active moieties chemically coupled to the polymer.
29. The polymer of claim 28 wherein the polymer is prepared from prepolymers formed by chemically coupling an α amino acid and an α hydroxy acid,
polymerizing the monomers, and
coupling biologically active moieties to free carboxylic acids, amino groups, sulfide groups, or hydroxyl groups on the amino acids.
30. The polymer of claim 29 wherein the
biologically active moieties are attachment peptides.
PCT/US1993/010655 1992-11-05 1993-11-05 Biodegradable polymers for cell transplantation WO1994009760A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP94901280A EP0619732B1 (en) 1992-11-05 1993-11-05 Biodegradable polymers for cell transplantation
DE69329903T DE69329903T2 (en) 1992-11-05 1993-11-05 BIODEGRADABLE POLYMERS FOR CELL TRANSPLANTATION
JP51143894A JP3288380B2 (en) 1992-11-05 1993-11-05 Biodegradable polymers for cell transplantation
AT94901280T ATE198980T1 (en) 1992-11-05 1993-11-05 BIODEGRADABLE POLYMERS FOR CELL TRANSPLANTATION
CA002127463A CA2127463C (en) 1992-11-05 1993-11-05 Biodegradable polymers for cell transplantation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US972,156 1992-11-05
US07/972,156 US5399665A (en) 1992-11-05 1992-11-05 Biodegradable polymers for cell transplantation

Publications (1)

Publication Number Publication Date
WO1994009760A1 true WO1994009760A1 (en) 1994-05-11

Family

ID=25519259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/010655 WO1994009760A1 (en) 1992-11-05 1993-11-05 Biodegradable polymers for cell transplantation

Country Status (8)

Country Link
US (1) US5399665A (en)
EP (1) EP0619732B1 (en)
JP (1) JP3288380B2 (en)
AT (1) ATE198980T1 (en)
CA (1) CA2127463C (en)
DE (1) DE69329903T2 (en)
ES (1) ES2156893T3 (en)
WO (1) WO1994009760A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6228423B1 (en) 1996-12-20 2001-05-08 Connaught Laboratories Limited Biodegradable targetable microparticle delivery system
CN100393753C (en) * 2005-07-04 2008-06-11 南开大学 Polymerization method of in-situ catalyzing atom transfer free radical by metal-guanidine complex
EP2039377A1 (en) * 2006-06-29 2009-03-25 Wuhan University Of Technology Rgd polypeptide grafted poly (glycolic acid-l-lysine-l-lactic acid) / -tricalcium phosphate composite material and preparation method thereof
US8268361B2 (en) 2005-10-26 2012-09-18 Ahlfors Jan-Eric W Acellular bioabsorbable tissue regeneration matrices
US8871236B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8871883B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible coating for implantable medical devices
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US9067000B2 (en) 2004-10-27 2015-06-30 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US9084671B2 (en) 2002-06-21 2015-07-21 Advanced Cardiovascular Systems, Inc. Methods of forming a micronized peptide coated stent
US9101697B2 (en) 2004-04-30 2015-08-11 Abbott Cardiovascular Systems Inc. Hyaluronic acid based copolymers
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9175162B2 (en) 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives
US9339592B2 (en) 2004-12-22 2016-05-17 Abbott Cardiovascular Systems Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US9364498B2 (en) 2004-06-18 2016-06-14 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US9580558B2 (en) 2004-07-30 2017-02-28 Abbott Cardiovascular Systems Inc. Polymers containing siloxane monomers
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US6132463A (en) * 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
AU729774B2 (en) * 1995-06-07 2001-02-08 T. J. Smith & Nephew Limited Stromal cell-based three-dimensional culture system for forming tubes, tendons, ligaments and corrective structures
US5654381A (en) * 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
US5908624A (en) * 1996-06-27 1999-06-01 Albany Medical College Antigenic modulation of cells
US8007784B1 (en) 1996-06-27 2011-08-30 Albany Medical College Antigenic modulation of cells
AU734691B2 (en) 1996-10-16 2001-06-21 Life Science Enterprises, Inc. Bioceramic compositions
US8728536B2 (en) * 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
ES2178102T3 (en) 1997-07-16 2002-12-16 Isotis Nv DEVICE FOR THE GENERATION OF OSEO TISSUE, WHICH INCLUDES A BIODEGRADABLE COPOLIESTER THERMOPLASTIC AND CULTIVATED CELLS.
US5925053A (en) 1997-09-02 1999-07-20 Children's Medical Center Corporation Multi-lumen polymeric guidance channel, method for promoting nerve regeneration, and method of manufacturing a multi-lumen nerve guidance channel
ZA9811377B (en) * 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
US6143293A (en) * 1998-03-26 2000-11-07 Carnegie Mellon Assembled scaffolds for three dimensional cell culturing and tissue generation
US6091979A (en) 1998-07-07 2000-07-18 Children's Medical Center Corporation Subdural electrode arrays for monitoring cortical electrical activity
US6245345B1 (en) 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6093792A (en) * 1998-09-16 2000-07-25 University Of Massachusetts Bioresorbable copolymers
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6703040B2 (en) 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
EP1370249A4 (en) * 2001-02-26 2006-05-03 Univ Duke Novel dendriticpolymers and their biomedical uses
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
WO2002096374A2 (en) * 2001-05-31 2002-12-05 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
DE60218061T2 (en) * 2001-10-22 2007-11-15 Massachusetts Institute Of Technology, Cambridge BIODEGRADABLE POLYMER
US7722894B2 (en) * 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
KR100515035B1 (en) * 2001-12-27 2005-09-15 한국과학기술원 Biodegradable Temperature-Sensitive Star-shaped Block Copolymer for Drug Delivery System
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
US20040131582A1 (en) * 2002-02-26 2004-07-08 Grinstaff Mark W. Novel dendritic polymers and their biomedical uses
US20040127563A1 (en) * 2002-03-22 2004-07-01 Deslauriers Richard J. Methods of performing medical procedures which promote bone growth, compositions which promote bone growth, and methods of making such compositions
US20030232088A1 (en) * 2002-06-14 2003-12-18 Kimberly-Clark Worldwide, Inc. Materials with both bioadhesive and biodegradable components
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
US20040028804A1 (en) * 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
EP2392359A3 (en) 2002-08-12 2012-03-07 Warsaw Orthopedic, Inc. Synthesis of a bone-polymer composite material
US7862831B2 (en) * 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US20050069572A1 (en) * 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
US6992543B2 (en) * 2002-11-22 2006-01-31 Raytheon Company Mems-tuned high power, high efficiency, wide bandwidth power amplifier
CA2521623C (en) * 2003-04-11 2015-03-17 Etex Corporation Osteoinductive bone material
JP4735260B2 (en) * 2003-07-07 2011-07-27 日油株式会社 Ternary block copolymer, production method thereof and biocompatible material
US8012210B2 (en) * 2004-01-16 2011-09-06 Warsaw Orthopedic, Inc. Implant frames for use with settable materials and related methods of use
US20060015184A1 (en) * 2004-01-30 2006-01-19 John Winterbottom Stacking implants for spinal fusion
CA2575740A1 (en) 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods
US8216359B2 (en) * 2004-04-15 2012-07-10 Etex Corporation Delayed-setting calcium phosphate pastes
US8791073B2 (en) * 2004-05-14 2014-07-29 William Marsh Rice University Peptide-modified polyurethane compositions and associated methods
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
DE602005022481D1 (en) * 2004-12-08 2010-09-02 Pervasis Therapeutics Inc COMPOSITIONS AND THEIR USE FOR BETTER VESSEL ACCESS
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
BRPI0608186A2 (en) * 2005-02-18 2011-01-04 Synthasome Inc synthetic structure for soft tissue repair
JP5174656B2 (en) * 2005-04-21 2013-04-03 マサチューセッツ インスティテュート オブ テクノロジー Materials and methods for modifying an immune response against exogenous and endogenous immunogens, including syngeneic or non-syngeneic cells, tissues or organs
CN102743792B (en) 2005-06-21 2014-09-24 夏尔再生医学公司 Methods and compositions for enhancing vascular access
US20070036842A1 (en) * 2005-08-15 2007-02-15 Concordia Manufacturing Llc Non-woven scaffold for tissue engineering
US20070042491A1 (en) * 2005-08-18 2007-02-22 Karp Jeffrey M Amplification of cell populations from embryonic stem cells
US20070100323A1 (en) * 2005-10-31 2007-05-03 Ludwig Florian N Facilitation of endothelialization by in situ surface modification
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US20090011486A1 (en) * 2006-01-12 2009-01-08 Massachusetts Institute Of Technology Biodegradable Elastomers
WO2007082304A2 (en) 2006-01-12 2007-07-19 Massachusetts Institute Of Technology Biodegradable elastomers
EP1976459A4 (en) * 2006-01-19 2012-06-20 Warsaw Orthopedic Inc Porous osteoimplant
WO2007084725A2 (en) * 2006-01-19 2007-07-26 Osteotech, Inc. Injectable and moldable bone substitute materials
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080193536A1 (en) * 2006-08-14 2008-08-14 Alireza Khademhosseini Cell-Laden Hydrogels
SG176460A1 (en) * 2006-11-07 2011-12-29 Pervasis Therapeutics Inc Materials and methods for treating and managing angiogenesis-mediated diseases
JP5258189B2 (en) * 2006-11-09 2013-08-07 学校法人 関西大学 Flexible biodegradable polymer
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US7935363B2 (en) 2006-12-12 2011-05-03 Synthasome, Inc. Composite material for tissue repair
EP2109641B1 (en) * 2007-01-17 2017-03-01 AgroFresh Inc. Delivery of ethylene blocking and/or promoting agents
WO2008098165A2 (en) * 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP5264103B2 (en) * 2007-05-09 2013-08-14 学校法人 関西大学 Biodegradable graft copolymer with temperature responsiveness
WO2008144514A2 (en) * 2007-05-17 2008-11-27 Massachusetts Institute Of Technology Polyol-based polymers
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
EP2162283B1 (en) 2007-06-14 2015-08-12 Massachusetts Institute of Technology Self assembled films for protein and drug delivery applications
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
ES2376175T3 (en) 2007-09-28 2012-03-09 Bind Biosciences, Inc. ADDRESS TO CELL? NCER CELLS USING NANOPART�? CULAS.
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009069123A2 (en) 2007-11-26 2009-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions comprising fibrous polypeptides and polysaccharides
US20100082072A1 (en) * 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
WO2010021973A2 (en) * 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
EA201791383A1 (en) 2009-05-27 2018-06-29 Селекта Байосайенсиз, Инк. NANOSEELS HAVE COMPONENTS WITH DIFFERENT RELEASE RATES
US9597430B2 (en) * 2009-07-31 2017-03-21 Synthasome, Inc. Synthetic structure for soft tissue repair
CN107617110A (en) 2009-08-26 2018-01-23 西莱克塔生物科技公司 The composition of inducing T cell auxiliary
AU2011217777B2 (en) * 2010-02-22 2014-08-14 Edge Therapeutics Inc. Methods and compositions to treat hemorrhagic conditions of the brain
NO2575876T3 (en) 2010-05-26 2018-05-05
US9549901B2 (en) 2010-09-03 2017-01-24 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
CN107115270A (en) 2011-02-11 2017-09-01 优势医疗公司 Composition and method for the prognosis of people of the improvement with subarachnoid hemorrhage
JP6336899B2 (en) 2011-04-05 2018-06-06 エッジ セラピューティクス インコーポレイテッド Intraventricular drug delivery system to improve outcome after brain injury affecting cerebral blood flow
EA201791679A1 (en) 2011-04-29 2018-09-28 Селекта Байосайенсиз, Инк. TOLEROGENIC SYNTHETIC NANO CARRIERS
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013020714A2 (en) 2011-08-11 2013-02-14 Qiagen Gmbh Cell- or virus simulating means comprising encapsulated marker molecules
CN102408389B (en) * 2011-09-15 2013-07-31 南开大学 Lactic acid-glutamic acid morpholine dione and synthetic process method thereof
JP6185489B2 (en) 2012-02-09 2017-08-23 ノーバス・インターナショナル・インコーポレイテッドNovus International,Inc. Functional polymer composition
EP2841056A4 (en) 2012-04-23 2015-09-16 Massachusetts Inst Technology Stable layer-by-layer coated particles
EP2841010B1 (en) 2012-04-24 2023-08-23 Harvard Apparatus Regenerative Technology, Inc. Supports for engineered tissue scaffolds
US9399019B2 (en) 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014004512A1 (en) 2012-06-25 2014-01-03 Surmodics, Inc. Bioerodable poly(etheresteramides) and medical article uses
CN104754956B (en) 2012-07-12 2017-11-17 诺华丝国际股份有限公司 For protecting the matrix and layer composition of bioactivator
US20140072611A1 (en) 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
WO2014110300A1 (en) 2013-01-09 2014-07-17 Harvard Apparatus Regenerative Technology Synthetic scaffolds
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
KR20150127206A (en) 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nanoparticle-based compositions
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
CN111686255A (en) 2013-05-03 2020-09-22 西莱克塔生物科技公司 Delivery of immunosuppressants and antigens with specific pharmacodynamic effective duration for induction of immune tolerance
IL295392A (en) 2013-06-04 2022-10-01 Selecta Biosciences Inc Repeated administration of non-immunosupressive antigen specific immunotherapeutics
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
MX2017002934A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses.
CN107072965B (en) 2014-11-05 2021-05-11 西莱克塔生物科技公司 Methods and compositions related to synthetic nanoparticles with rapamycin in a stable supersaturated state
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017117188A1 (en) 2015-12-29 2017-07-06 Massachusetts Institute Of Technology Biodegradable free-standing controlled drug release stickers
EP3416686A1 (en) 2016-02-16 2018-12-26 Dana Farber Cancer Institute, Inc. Immunotherapy compositions and methods
EP3426285A1 (en) 2016-03-11 2019-01-16 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CA3038089A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
JP2020502062A (en) 2016-11-17 2020-01-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Alkylpyrrolopyrimidine analogs and methods of making and using same
JP2020506890A (en) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. Patterned administration of immunosuppressants coupled to synthetic nanocarriers
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018187688A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
US20200249194A9 (en) 2017-10-12 2020-08-06 Massachusetts Institute Of Technology Prostate protease nanosensors and uses thereof
CA3078705A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US20210115378A1 (en) 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
CA3106640A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of mma constructs and vectors
KR20210032438A (en) 2018-07-16 2021-03-24 셀렉타 바이오사이언시즈, 인크. Methods and compositions of OTC constructs and vectors
US20200096514A1 (en) 2018-09-25 2020-03-26 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3867396A2 (en) 2018-10-16 2021-08-25 Massachusetts Institute of Technology Renal clearable nanocatalysts for disease monitoring
EP3866773A4 (en) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
JP2022534741A (en) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for attenuated antiviral transduction vector immune response
CA3138071A1 (en) 2019-06-04 2020-12-10 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
CA3158408A1 (en) 2019-10-21 2021-04-29 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
AU2020380944A1 (en) 2019-11-08 2022-06-02 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
US20210262025A1 (en) 2020-02-18 2021-08-26 Massachusetts Institute Of Technology Multiplexed in vivo disease sensing with nucleic acid-barcoded reporters
MX2022010568A (en) 2020-02-26 2022-11-30 Selecta Biosciences Inc Methods and compositions using synthetic nanocarriers comprising immunosuppressant.
CN115484931A (en) 2020-03-11 2022-12-16 西莱克塔生物科技公司 Methods and compositions related to synthetic nanocarriers
JP2023530385A (en) 2020-04-14 2023-07-18 セレクタ バイオサイエンシーズ インコーポレーテッド Methods and compositions for inducing autophagy
US20220133864A1 (en) 2020-11-04 2022-05-05 Selecta Biosciences, Inc. Methods and compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673566A (en) * 1983-06-01 1987-06-16 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4696286A (en) * 1985-03-14 1987-09-29 The Regents Of The University Of California Coated transplants and method for making same
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US5010167A (en) * 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5248761A (en) * 1992-08-12 1993-09-28 United States Surgical Corporation Amino acid terminated polyesters having predetermined monomeric sequence

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676945A (en) * 1950-10-18 1954-04-27 Du Pont Condensation polymers of hydroxyacetic acid
US2668162A (en) * 1952-03-20 1954-02-02 Du Pont Preparation of high molecular weight polyhydroxyacetic ester
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4048256A (en) * 1976-06-01 1977-09-13 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4441496A (en) * 1982-02-08 1984-04-10 Ethicon, Inc. Copolymers of p-dioxanone and 2,5-morpholinediones and surgical devices formed therefrom having accelerated absorption characteristics
WO1992015676A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Somatic cell gene therapy
US5215278A (en) * 1991-12-02 1993-06-01 Hess Douglas S Apparatus for laying turf

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673566A (en) * 1983-06-01 1987-06-16 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4689293A (en) * 1983-06-06 1987-08-25 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4806355A (en) * 1983-06-06 1989-02-21 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4696286A (en) * 1985-03-14 1987-09-29 The Regents Of The University Of California Coated transplants and method for making same
US5010167A (en) * 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5248761A (en) * 1992-08-12 1993-09-28 United States Surgical Corporation Amino acid terminated polyesters having predetermined monomeric sequence

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6228423B1 (en) 1996-12-20 2001-05-08 Connaught Laboratories Limited Biodegradable targetable microparticle delivery system
US6287604B1 (en) 1996-12-20 2001-09-11 Aventis Pasteur Limited Biodegradable targetable microparticle delivery system
US6312732B1 (en) 1996-12-20 2001-11-06 Aventis Pasteur Limited/Aventus Pasteur Limitee Biodegradable targetable microparticle delivery system
US6471996B1 (en) 1996-12-20 2002-10-29 Aventis Pasteur Limited Biodegradable targetable microparticle delivery system
US6623764B1 (en) 1996-12-20 2003-09-23 Aventis Pasteur Limited Biodegradable targetable microparticle delivery system
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US8961588B2 (en) 2002-03-27 2015-02-24 Advanced Cardiovascular Systems, Inc. Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin
US9084671B2 (en) 2002-06-21 2015-07-21 Advanced Cardiovascular Systems, Inc. Methods of forming a micronized peptide coated stent
US8986726B2 (en) 2002-12-11 2015-03-24 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8871236B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible polyacrylate compositions for medical applications
US8871883B2 (en) 2002-12-11 2014-10-28 Abbott Cardiovascular Systems Inc. Biocompatible coating for implantable medical devices
US9175162B2 (en) 2003-05-08 2015-11-03 Advanced Cardiovascular Systems, Inc. Methods for forming stent coatings comprising hydrophilic additives
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US9101697B2 (en) 2004-04-30 2015-08-11 Abbott Cardiovascular Systems Inc. Hyaluronic acid based copolymers
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US9364498B2 (en) 2004-06-18 2016-06-14 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9375445B2 (en) 2004-06-18 2016-06-28 Abbott Cardiovascular Systems Inc. Heparin prodrugs and drug delivery stents formed therefrom
US9580558B2 (en) 2004-07-30 2017-02-28 Abbott Cardiovascular Systems Inc. Polymers containing siloxane monomers
US9067000B2 (en) 2004-10-27 2015-06-30 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US9339592B2 (en) 2004-12-22 2016-05-17 Abbott Cardiovascular Systems Inc. Polymers of fluorinated monomers and hydrocarbon monomers
CN100393753C (en) * 2005-07-04 2008-06-11 南开大学 Polymerization method of in-situ catalyzing atom transfer free radical by metal-guanidine complex
US8268361B2 (en) 2005-10-26 2012-09-18 Ahlfors Jan-Eric W Acellular bioabsorbable tissue regeneration matrices
US9314420B2 (en) 2005-10-26 2016-04-19 Jan-Eric Ahlfors Acellular bioabsorbable tissue regeneration matrices
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
EP2039377A1 (en) * 2006-06-29 2009-03-25 Wuhan University Of Technology Rgd polypeptide grafted poly (glycolic acid-l-lysine-l-lactic acid) / -tricalcium phosphate composite material and preparation method thereof
EP2039377A4 (en) * 2006-06-29 2011-11-02 Univ Wuhan Tech Rgd polypeptide grafted poly (glycolic acid-l-lysine-l-lactic acid) / -tricalcium phosphate composite material and preparation method thereof
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device

Also Published As

Publication number Publication date
JP3288380B2 (en) 2002-06-04
DE69329903D1 (en) 2001-03-08
DE69329903T2 (en) 2001-07-19
ES2156893T3 (en) 2001-08-01
ATE198980T1 (en) 2001-02-15
EP0619732A4 (en) 1995-02-22
EP0619732A1 (en) 1994-10-19
JPH07506622A (en) 1995-07-20
CA2127463A1 (en) 1994-05-11
CA2127463C (en) 2005-07-05
US5399665A (en) 1995-03-21
EP0619732B1 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
EP0619732B1 (en) Biodegradable polymers for cell transplantation
JP4376455B2 (en) Polyhydroxyalkanoate composition having controlled degradation rate
Barrera et al. Copolymerization and degradation of poly (lactic acid-co-lysine)
US7244442B2 (en) Method for making devices using polyhydroxyalkanoate having pyrogen removed
US6878758B2 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
US6867248B1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
US6828357B1 (en) Polyhydroxyalkanoate compositions having controlled degradation rates
Chen et al. The use of poly (l-lactide) and RGD modified microspheres as cell carriers in a flow intermittency bioreactor for tissue engineering cartilage
Chawla et al. In-vivo degradation of poly (lactic acid) of different molecular weights
KR100684940B1 (en) Method for differentiating mesenchymal stem cell to chondrocyte using fibrin/ha containing scaffold
WO2003042277A1 (en) The polyester containing active drugs and having amino acids in the main chain, and its preparation method
Sawhney et al. Polymer synthesis
JP4674331B2 (en) Cell / tissue culture substrate and host embedded structure
WO2023231045A1 (en) Hyperbranched polylysine-containing polyurethane heart patch and preparation method therefor
Barrera Synthesis and characterization of a novel biodegradable polymer--poly (lactic acid-co-lysine)
Somerville Williams et al.
JP4548644B2 (en) Biomaterial
Elbert et al. Multifunctional organic polymers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2127463

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994901280

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1994901280

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994901280

Country of ref document: EP